Medicus Pharma's (MDCX) Buy Rating Reaffirmed at D. Boral Capital

Medicus Pharma (NASDAQ:MDCX - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $27.00 price target on the stock. D. Boral Capital's target price suggests a potential upside of 250.19% from the company's previous close.

MDCX has been the subject of a number of other research reports. Maxim Group increased their price target on shares of Medicus Pharma from $10.00 to $20.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. D Boral Capital raised shares of Medicus Pharma to a "strong-buy" rating in a report on Monday, April 14th.

Medicus Pharma Stock Up 1.3%

Shares of NASDAQ MDCX opened at $7.71 on Thursday. The company's 50 day moving average is $4.20. Medicus Pharma has a 52 week low of $1.80 and a 52 week high of $8.94.

Medicus Pharma (NASDAQ:MDCX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.19). As a group, equities research analysts anticipate that Medicus Pharma will post -1.14 EPS for the current year.

Insider Buying and Selling at Medicus Pharma

In related news, major shareholder Velocity Fund Partners, Lp sold 75,000 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $7.72, for a total value of $579,000.00. Following the transaction, the insider now owns 3,248,741 shares in the company, valued at approximately $25,080,280.52. This represents a 2.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Institutional Investors Weigh In On Medicus Pharma

Several hedge funds have recently bought and sold shares of MDCX. Armistice Capital LLC acquired a new position in shares of Medicus Pharma in the first quarter valued at approximately $4,710,000. Private Advisor Group LLC acquired a new stake in Medicus Pharma during the 1st quarter worth approximately $211,000. Finally, Interchange Capital Partners LLC boosted its stake in Medicus Pharma by 14.0% in the 1st quarter. Interchange Capital Partners LLC now owns 1,661,871 shares of the company's stock valued at $6,182,000 after purchasing an additional 204,706 shares during the period.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.